title: Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.
authors.forename: R J
authors.initials: RJ
authors.lastname: Mayer
authors.forename: C A
authors.initials: CA
authors.lastname: Schiffer
authors.forename: B A
authors.initials: BA
authors.lastname: Peterson
authors.forename: D R
authors.initials: DR
authors.lastname: Budman
authors.forename: R T
authors.initials: RT
authors.lastname: Silver
authors.forename: K R
authors.initials: KR
authors.lastname: Rai
authors.forename: G G
authors.initials: GG
authors.lastname: Cornwell
authors.forename: R R
authors.initials: RR
authors.lastname: Ellison
authors.forename: M
authors.initials: M
authors.lastname: Maguire
authors.forename: D T
authors.initials: DT
authors.lastname: Berg
mesh_terms: D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D003561:Cytarabine; D003630:Daunorubicin